Cell signaling

• Control of glutamate release by complexes of adenosine and cannabinoid receptors (24 Sep 2024)
  
• Cannabis hyperemesis syndrome: an update on the pathophysiology and management (16 Sep 2024)
  
• Comparing CB1 receptor GIRK channel responses to receptor internalization using a kinetic imaging assay (03 Sep 2024)
  
• Cannabinoids and triple-negative breast cancer treatment (03 Sep 2024)
  
• The Relationship between Muscarinic and Cannabinoid Receptors in Neuronal Excitability and Epilepsy: A Review (02 Sep 2024)
  
• The Interplay between Cannabinoid Receptors and Microglia in the Pathophysiology of Alzheimer’s Disease (02 Sep 2024)
  
• The Implications of Cannabinoid-Induced Metabolic Dysregulation for Cellular Differentiation and Growth (02 Sep 2024)
  
• The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update (02 Sep 2024)
  
• The effect of cannabinoid type 2 receptor agonist on morphine tolerance (02 Sep 2024)
  
• Probing the Conformational Space of the Cannabinoid Receptor 2 and a Systematic Investigation of DNP (02 Sep 2024)
  
• Perturbation of 3D nuclear architecture, epigenomic dysregulation and aging, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 1–aging and epigenomics (02 Sep 2024)
  
• Perturbation of 3D nuclear architecture, epigenomic aging and dysregulation, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 2—Metabolome, immunome, synaptome (02 Sep 2024)
  
• Hexahydrocannabinol (HHC) and Δ9-tetrahydrocannabinol (Δ9-THC) driven activation of cannabinoid receptor 1 results in biased intracellular signaling (02 Sep 2024)
  
• Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists (02 Sep 2024)
  
• Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity (02 Sep 2024)
  
• Development of a membrane-based Gi-CASE biosensor assay for profiling compounds at cannabinoid receptors (02 Sep 2024)
  
• Cannabinoid receptors type 2: Function and development in agonist discovery from synthetic and natural sources with applications for the therapy of osteoporosis (02 Sep 2024)
  
• Cannabinoid receptor 2 signal promotes type 2 immunity in the lung (02 Sep 2024)
  
• Cannabinoid and Orexigenic Systems Interplay as a New Focus of Research in Alzheimer’s Disease (02 Sep 2024)
  
• Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality (02 Sep 2024)
  
• Assessment of the proliferative and angiogenic effects of the synthetic cannabinoid (R)-5-fluoro ADB on human cerebral microvascular endothelial cells (02 Sep 2024)
  
• A collection of cannabinoid-related negative findings from autaptic hippocampal neurons (30 Aug 2024)
  
• Neuronal Cannabinoid CB1 Receptors Suppress the Growth of Melanoma Brain Metastases by Inhibiting Glutamatergic Signalling (29 Aug 2024)
  
• Cannabinoid Signaling in Kidney Disease (29 Aug 2024)
  
• Cannabinoid Receptor 1 Agonist ACEA and Cannabinoid Receptor 2 Agonist GW833972A Attenuates Cell-Mediated Immunity by Different Biological Mechanisms (29 Aug 2024)
  
• Cannabinoid and Opioid Receptor Affinity and Modulation of Cancer-Related Signaling Pathways of Machaeriols and Machaeridiols from Machaerium Pers. (29 Aug 2024)
  
• Understanding the Dynamics of the Structural States of Cannabinoid Receptors and the Role of Different Modulators (28 Aug 2024)
  
• The endocannabinoid systemʼs involvement in motor development relies on cannabinoid receptors, TRP channels, and Sonic Hedgehog signaling (28 Aug 2024)
  
• Microglial Cannabinoid CB2 Receptors in Pain Modulation (28 Aug 2024)
  
• Voltage dependence of the cannabinoid CB1 receptor (27 Aug 2024)
  
• The Enteric Glia and Its Modulation by the Endocannabinoid System, a New Target for Cannabinoid-Based Nutraceuticals? (27 Aug 2024)
  
• Synthetic cannabinoid WIN 55,212–2 inhibits growth and induces cell death of oral and pancreatic stem-like/poorly differentiated tumor cells (27 Aug 2024)
  
• Evaluation of cannabinoid receptors type 1–2 in periodontitis patients (27 Aug 2024)
  
• Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential (27 Aug 2024)
  
• A Crosstalk between the Cannabinoid Receptors and Nociceptin Receptors in Colitis—Clinical Implications (27 Aug 2024)
  
• Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits (25 Aug 2024)
  
• Cannabinoid Receptor-1 suppresses M2 macrophage polarization in colorectal cancer by downregulating EGFR (25 Aug 2024)
  
• Activation of cannabinoid receptors in breast cancer cells improves osteoblast viability in cancer-bone interaction model while reducing breast cancer cell survival and migration (25 Aug 2024)
  
• The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors (21 Aug 2024)
  
• Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease (21 Aug 2024)
  
• Receptor-targeted nanoparticles modulate cannabinoid anticancer activity through delayed cell internalization (21 Aug 2024)
  
• Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death (21 Aug 2024)
  
• MD Simulations Revealing Special Activation Mechanism of Cannabinoid Receptor 1 (21 Aug 2024)
  
• Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R) (20 Aug 2024)
  
• High Expression of Cannabinoid Receptor 2 on Cytokine-Induced Killer Cells and Multiple Myeloma Cells (20 Aug 2024)
  
• Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases (20 Aug 2024)
  
• Cholesterol as a modulator of cannabinoid receptor CB2 signaling (20 Aug 2024)
  
• Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity (20 Aug 2024)
  
• Cannabinoids and Cannabinoid Receptors: The Story so Far (20 Aug 2024)
  
• Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases (20 Aug 2024)
  
• Cannabinoid Receptor 1/miR-30b-5p Axis Governs Macrophage NLRP3 Expression and Inflammasome Activation in Liver Inflammatory Disease (20 Aug 2024)
  
• Cannabinoid Modulation of Dopamine Release During Motivation, Periodic Reinforcement, Exploratory Behavior, Habit Formation, and Attention (20 Aug 2024)
  
• The Modulating Role of Sex and Anabolic-Androgenic Steroid Hormones in Cannabinoid Sensitivity (19 Aug 2024)
  
• Structure–Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives (19 Aug 2024)
  
• Phosphorylation of extracellular signal-regulated kinase as a biomarker for cannabinoid receptor 2 activation (19 Aug 2024)
  
• Down-Regulation of Cannabinoid Type 1 (CB1) Receptor and its Downstream Signaling Pathways in Metastatic Colorectal Cancer (19 Aug 2024)
  
• Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System (19 Aug 2024)
  
• Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines (19 Aug 2024)
  
• Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: An In Silico study (19 Aug 2024)
  
• Brain-Derived Neurotrophic Factor (BDNF) Role in Cannabinoid-Mediated Neurogenesis (19 Aug 2024)
  
• Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges (18 Aug 2024)
  
• Synthetic Ligands of Cannabinoid Receptors Affect Dauer Formation in the Nematode Caenorhabditis elegans (18 Aug 2024)
  
• Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics (18 Aug 2024)
  
• Effect of interaction between acute administration of morphine and cannabinoid compounds on spontaneous excitatory and inhibitory postsynaptic currents of magnocellular neurons of supraoptic nucleus (18 Aug 2024)
  
• Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System (18 Aug 2024)
  
• Cannabinoid receptor type-1: breaking the dogmas (18 Aug 2024)
  
• Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor Complexes (18 Aug 2024)
  
• The Cannabinoid Receptor CB1 Interacts with the WAVE1 Complex and Plays a Role in Actin Dynamics and Structural Plasticity in Neurons (12 Aug 2024)
  
• Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation (12 Aug 2024)
  
• Inflammation and cancer: friend or foe? (24 May 2024)
  
• N-Methyl-D-aspartate (NMDA) and cannabinoid CB2 receptors form functional complexes in cells of the central nervous system: insights into the therapeutic potential of neuronal and microglial NMDA rece (13 May 2024)
  
• Cannabinoid Receptor 1 Blockade Attenuates Obesity and Adipose Tissue Type 1 Inflammation Through miR-30e-5p Regulation of Delta-Like-4 in Macrophages and Consequently Downregulation of Th1 Cells (13 May 2024)
  
• Beta-Caryophyllene Exhibits Anti-Proliferative Effects through Apoptosis Induction and Cell Cycle Modulation in Multiple Myeloma Cells (27 Nov 2022)
  
• The Impact of CB1 Receptor on Nuclear Receptors in Skeletal Muscle Cells (05 Sep 2022)
  
• Quality of Life and a Surveillant Endocannabinoid System (05 Sep 2022)
  
• N-Methyl-D-aspartate (NMDA) and cannabinoid CB2 receptors form functional complexes in cells of the central nervous system: insights into the therapeutic potential of neuronal and microglial NMDA receptors (01 Sep 2022)
  
• Identification of Novel Antagonists Targeting Cannabinoid Receptor 2 Using a Multi-Step Virtual Screening Strategy (01 Sep 2022)
  
• Gene Expression Data Mining Reveals the Involvement of GPR55 and Its Endogenous Ligands in Immune Response, Cancer, and Differentiation (01 Sep 2022)
  
• CB2 Receptor in Microglia: The Guardian of Self-Control (01 Sep 2022)
  
• The systems medicine of cannabinoids in pediatrics: the case for more pediatric studies (27 Aug 2022)
  
• 1,2,3-Triazole derivatives as highly selective cannabinoid receptor type 2 (CB2) agonists (27 Aug 2022)
  
• Cannabinoids in Chronic Pain: Therapeutic Potential Through Microglia Modulation (13 Aug 2022)
  
• The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation (05 Aug 2022)
  
• Targeting the Endocannabinoidome in Pancreatic Cancer (05 Aug 2022)
  
• Endocannabinoid-Mediated Control of Neural Circuit Excitability and Epileptic Seizures (05 Aug 2022)
  
• Chronic Pain and the Endocannabinoid System: Smart Lipids – A Novel Therapeutic Option? (05 Aug 2022)
  
• Cannabinoids, their cellular receptors, and effects on the invasive phenotype of carcinoma and metastasis (05 Aug 2022)
  
• Botanically-Derived Δ9-Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis (05 Aug 2022)
  
• Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action (31 Jul 2022)
  
• A critical review of cannabis in medicine and dentistry: A look back and the path forward (31 Jul 2022)
  
• Endothelial dysfunction and angiogenesis: what is missing from COVID-19 and cannabidiol story? - Journal of Cannabis Research (26 Jul 2022)
  
• Combination of cannabidiol with low‑dose naltrexone increases the anticancer action of chemotherapy in vitro and in vivo (25 Jul 2022)
  
• Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review (21 Jul 2022)
  
• CBD & the Psychedelic Receptor (21 Jul 2022)
  
• Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease (20 Jul 2022)